BeiGene, Ltd. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2022. The filing identifies the registrant as BeiGene, Ltd. (not “Beone Medicines Ltd.”). Figures below are in U.S. dollars; financial statement amounts are summarized in millions unless noted.
Business context
BeiGene is a global oncology biotechnology company developing and commercializing its own medicines and distributing licensed products. Its key internally developed products include BRUKINSA, tislelizumab and pamiparib. It also has commercial and development collaborations with Amgen and Novartis. The company reported one operating segment.
Key financial results
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Product revenue, net | $304.5M | $138.6M | $566.1M | $244.7M |
| Collaboration revenue | $37.1M | $11.4M | $82.1M | $511.1M |
| Total revenue | $341.6M | $150.0M | $648.2M | $755.9M |
| Operating loss | $439.4M | $474.8M | $882.7M | $404.7M |
| Net loss | $571.4M | $480.3M | $1,005.7M | $413.8M |
| Operating cash used | Not separately stated | Not separately stated | $616.5M | $295.2M |
Margins and expenses: Product gross margin was 76.6% in Q2 and 75.9% for the first half, compared with 73.8% and 71.8%, respectively, in the prior-year periods. R&D expense was $378.2M in Q2 and $768.1M for the first half; SG&A was $331.4M and $626.0M, respectively. The filing attributes higher SG&A and internal R&D costs mainly to expansion of global commercial and development teams and operations.
Liquidity and debt: At June 30, cash, cash equivalents and restricted cash were $4.535B, and short-term investments were $1.173B. Total debt was $565.9M, comprising $380.7M short-term debt and $185.2M long-term bank loans. Current assets were $6.346B versus current liabilities of $1.398B. Management stated that existing cash, cash equivalents and short-term investments were expected to fund operating expenses and capital requirements for at least 12 months after issuance of the financial statements.
Changes versus prior comparable periods
- Q2 total revenue rose 127.7%, driven chiefly by product revenue growth of 119.7%. BRUKINSA revenue reached $128.7M, up 203.5%; tislelizumab was $104.9M, up 40.1%.
- First-half total revenue fell 14.2% despite product revenue growth of 131.3%, because first-half 2021 included $484.6M of Novartis tislelizumab license revenue recognized upfront.
- First-half operating loss increased to $882.7M from $404.7M, and net loss increased to $1.006B from $413.8M. The 2022 period included substantially higher operating costs and other expense.
- First-half operating cash use more than doubled year over year, from $295.2M to $616.5M.
- Cash, cash equivalents and restricted cash increased $152.5M from year-end 2021, while short-term investments declined by about $1.069B. Investing cash inflow included $1.051B of investment sales and maturities.
Outlook, commentary, risks and unusual items
- Outlook: The filing gives no specific revenue or earnings guidance. Management expects R&D and SG&A costs to increase as development programs, commercialization and global capabilities expand; it also expects significant capital spending on manufacturing and R&D facilities.
- Regulatory developments: In July 2022, the FDA deferred action on the tislelizumab BLA for second-line unresectable or metastatic esophageal squamous cell carcinoma because it could not complete inspections amid travel restrictions; no new action date was provided. The FDA extended the BRUKINSA CLL/SLL application goal date to January 20, 2023 to review additional clinical data.
- Unusual non-operating expense: Other expense was $129.6M in Q2 and $117.7M for the first half, primarily from foreign-exchange losses tied to U.S.-dollar strengthening and revaluation of foreign-currency balances held by U.S.-functional-currency subsidiaries. The first-half cash-flow statement also reports a $71.2M adverse exchange-rate effect on cash.
- Other investment loss: The company recorded $22.7M of unrealized losses on its Leap Therapeutics investment in the first half, contributing to other expense.
- Commitments: Contractual and other obligations totaled $1.840B, including $308.1M of capital commitments, $698.7M remaining Amgen co-development funding, and $565.9M of debt obligations. Potential future milestone payments on in-licensed technology totaled $5.7B; these are contingent and not recorded as balance-sheet liabilities.
- Contingency: BeiGene is in arbitration with BMS-Celgene concerning the ABRAXANE China license and supply agreement. BMS-Celgene counterclaimed for approximately $30M; BeiGene disputes the claim. The arbitration hearing took place in June 2022, with no decision reported.
- Key risks: Ongoing losses and cash burn; uncertain clinical and regulatory outcomes; drug pricing and reimbursement pressure; dependence on third-party manufacturing and collaborators; foreign-exchange exposure; PRC regulatory, data-security and cross-border data risks; and U.S. listing/audit inspection risk under the HFCAA. The company said its 2022 auditor would be Ernst & Young LLP in the United States and expected this to address PCAOB inspection requirements, subject to applicable requirements.
Important facts for investors to verify
- Whether product growth, particularly BRUKINSA and tislelizumab, can continue to offset pricing pressure, operating cost growth and collaboration-revenue variability.
- Cash runway assumptions against the reported $616.5M first-half operating cash use and $308.1M capital commitments.
- Timing and outcome of the FDA reviews for tislelizumab and BRUKINSA, including inspection constraints and any updated regulatory dates.
- Exposure to currency movements, including the $129.6M Q2 other expense and the impact of RMB and other currencies on cash and earnings.
- Developments in the BMS-Celgene arbitration, including the counterclaim and potential financial or commercial consequences.
- Progress on manufacturing expansion, the Amgen co-development commitment, and compliance with evolving PRC data and overseas-listing requirements.